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Probiotics and Cardiovascular Disease
Abstract

Cardiovascular disease is the leading cause of mortality worldwide, regardless of gender.
Prevention is key in decreasing morbidity and mortality. Because of this, prevention is geared
toward decreasing the risk factors of cardiovascular disease. Some risk factors cannot be avoided
such as family history, genetics, or gender but there are many risk factors that can be avoided or
modified. These risk factors include hypertension, hyperlipidemia, obesity, tobacco use,
sedentary lifestyle, and an unhealthy diet. The case report presented is a post-menopausal female
with hypertension. Other than hypertension she has several other risk factors for cardiovascular
disease such as a positive family history, unhealthy diet, and borderline high cholesterol.
Treatment and prevention of her cardiovascular risk factors include controlling her blood
pressure and cholesterol. Interventions include lifestyle changes, such as dietary modifications
and exercise, and blood pressure medication. Probiotics are discussed in this report as part of diet
modification for the female patient. New research has been found linking probiotics to their
ability in regulating blood pressure, cholesterol, and a healthy weight through the modulation of
the gut microbiota. Studies have shown the therapeutic and cost-effective potential of the use of
probiotics in managing cholesterol and hypertension in the future. Further studies are warranted
to determine what probiotic strains and the amount needed to be ingested to gain the greatest
cardiovascular benefit.
Background
Cardiovascular disease is the number one cause of the death worldwide for both men and
women (World Health Organization, 2016). Cardiovascular disease encompasses diseases that
affect the vasculature of the heart and blood vessels which includes but are not limited to
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coronary artery disease, cerebral vascular disease, and peripheral arterial disease. Cardiovascular
disease can significantly be prevented with interventions to target the risk factors of
cardiovascular disease (World Health Organization, 2016). Some risk factors for cardiovascular
disease are not modifiable, such as male gender, advancing age, family history of cardiovascular
disease, and being African American. Modifiable risk factors include hypertension, tobacco use,
sedentary lifestyle, and hyperlipidemia. Other factors that contribute to cardiovascular disease
are obesity, stress, and Diabetes mellitus (Dunphy et al., 2015). The modifiable risk factors are
what is targeted by therapeutic measures. Regular physicals are necessary to identify
cardiovascular risk factors or problems such as with monitoring blood pressure and cholesterol
so that lifestyle changes and medications can be started to protect cardiovascular health (Direnzo,
2013).
The increased prevalence of cardiovascular diseases is mostly due to the inadequate and
unsuccessful use of preventative interventions. Therefore, there is a dire need to continue
developing innovative strategies to both prevent and treat cardiovascular disease. Proper diet and
nutrition are crucial in decreasing the risk of cardiovascular disease and to protect and enhance
cardiovascular function in those already with cardiovascular disease. New research is showing
that probiotics may have the ability to reduce both cholesterol and hypertension, two major risk
factors of cardiovascular disease, through the modulation of the gut flora or microbiota. An
impaired balance of the gut microbiota has also been linked to obesity another risk factor for
cardiovascular disease. This suggests that rebalancing the gut microbiota makeup with the use of
probiotics may contribute to the ability to maintain a healthy weight and metabolism (Yadav &
Jain, 2013). The use of probiotics may be able to positively influence cardiovascular health
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through many different avenues especially when used in conjunction with other lifestyle and diet
modifications.
Case Report
Kathy is a 67-year-old female that presents to the clinic for a follow up on her
hypertension. Three weeks ago, she started on Lisinopril 20 mg daily. Her blood pressures at
home has been running in the 150s to 160s systolic and the 70s to 80s diastolic. However, since
starting on the Lisinopril she has developed a dry cough that she describes as annoying. It wakes
her up at night. It occurs off and on throughout the day. She denies any shortness of breath,
dizziness, or chest pain. She also denies any recent upper respiratory infection, nasal congestion,
or nasal drainage. Her cholesterol was checked six months ago which was borderline. The only
other medication she is taking is a Multivitamin daily. She has no known drug allergies. She has
no history of cardiac issues including stroke, heart attack, or chest pain. She does not use
tobacco. Her mother and father are no longer living. Her mother and father both had a long
history of hypertension. Her mother had an abdominal aortic aneurism. Her dad had a coronary
bypass and Squamous Cell Carcinoma. She has two children who are both healthy.
The physical exam revealed S1 and S2 at a regular rate and rhythm. No murmurs noted.
PMI nondisplaced. Lung sounds clear bilaterally to posterior and anterior lung fields. Dry
intermittent cough noted. No signs of respiratory distress. Bilateral tympanic membranes pearly
gray. Cone of light present to bilateral tympanic membranes. Posterior oropharynx pink and
moist. Tonsils +1 bilaterally. The nasopharynx is pink and non-edematous. A complete
metabolic panel was done three weeks ago which was in normal range. Lipid panel checked six
months ago which was borderline high. Her vital signs today were blood pressure 160/98, pulse
80, respiratory rate 20, and temperature 98.6.
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Assessment is an ACE Inhibitor induced cough. Plan is to discontinue the Lisinopril
today and to start Losartan 50 mg orally daily. She will return in three weeks to recheck her
blood pressure and have a complete metabolic panel drawn. Explained to patient the complete
metabolic panel will be done to assess how the kidneys are handling the new medication. She
should continue to check her blood pressure daily and write it down. Discussed that the Losartan
may need to be either increased or another medication added to her regimen since her blood
pressure is still high with the Lisinopril. A lipid panel will also be rechecked in about six months.
Discussed with patient that she may be able to decrease her cholesterol with lifestyle changes
alone. She has started doing water aerobics three times a week which she enjoys. Encouraged to
continue exercising several times a week. She also has started to eat healthier but asks for
education regarding a healthy diet. Discussed the DASH diet and gave her written information.
Discussed the use of probiotics as part of the DASH diet, as new evidence has showed the
potential of probiotics to decrease cholesterol, blood pressure, and promote a healthy weight. She
states she saw what cardiovascular problems did to her parents and she would like to avoid any
for herself if possible. Discussed that modifying her modifiable risk factors with lifestyle
changes such as diet and exercise will help to increase her cardiovascular health and decrease her
risk factors in developing cardiovascular problems in the future.
Literature Review
Interventions to decrease cardiovascular disease and improve cardiovascular health are
primarily done by modifying risk factors. There are non-modifiable risk factors for
cardiovascular disease such as genetics; but there are many modifiable risk factors that if
modified can decrease the risk of cardiovascular disease. These modifications include exercise,
sustaining a healthy body mass index (BMI), not using tobacco, and diet changes such as
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decreasing saturated fat, trans fat, and cholesterol. One of the biggest risk factors for
cardiovascular disease is having a high low density lipid protein (LDL). Thus, one of the main
priorities for treatment is decreasing the LDL (DiRienzo, 2013).
Coronary artery disease is the leading cause of death and high cholesterol contributes
directly (Tomaro-Duchesneau et al., 2014). Elevated LDL in the blood is a precursor to high
blood pressure and triggers the formation of an atherosclerotic plaque in the arteries (DiRienzo,
2013). Because of this it is necessary to continue studying different options in preventing and
treating high cholesterol (Tomaro-Duchesneau et al., 2014). High triglycerides and low highdensity lipid proteins (HDL) are also risk factors but are treated secondarily. Statins are the firstline medication for treating elevated LDL but should come after dietary and lifestyle
modifications are ineffective (DiRienzo, 2013).
Likewise, dietary and lifestyle modifications should continue with the use of statins or
other medications that lower cholesterol or blood pressure. Non-pharmacologic therapies need to
be investigated because some people do not tolerate statins or they are not at high enough risk to
need a statin. Non-pharmacologic therapy may not always decrease cholesterol as well as a statin
but will still lower cholesterol without the side effects. Also, combining dietary modifications
with medications may show the best results. In fact, dietary modifications with the use of
probiotics may show similar results in decreasing LDL compared to a diet alone low in saturated
fat and cholesterol (DiRienzo, 2013).
Probiotics are mostly recognized for their use in preventing diarrhea caused by the use of
antibiotics. However, their ability to positively impact cardiovascular health by decreasing
cholesterol and hypertension is not as well-known (Tomaro-Duchesneu et al., 2014). A metaanalysis of randomized controlled trials looked at 485 participants with high, borderline high, or
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normal LDL and results showed that LDL and total cholesterol levels dropped significantly with
those who ingested the probiotics compared to the control group. It is thought that gram-positive
bacteria in the gut microbiota influence an increase in the catabolism of cholesterol through an
enzyme called bile salt hydrolise. Bacteria that produce a high amount of this enzyme are able to
break down bile salts, which are a precursor to cholesterol, so that they are excreted from the
body. The body then breaks down cholesterol to replace these broken down bile salts, thus
lowing serum cholesterol (Ettinger et al., 2014).
A review by Tuohy, Fava, and Viola (2014) was done to discuss this recently found
association between the human gut microbiota and cardiovascular disease, as well as how the gut
microbiota can be influenced by diet. Fruits, vegetables, and whole grains have long been
considered part of a heart healthy diet. New research now shows that they increase the diversity
of gut microbiota, since they include great amounts of fiber, prebiotics, and polyphenols. These
findings suggest that it is by modifying the gut microbiota that these foods are retrieving part of
their cardiovascular benefits. For example, red meat, low fiber, and high fat have long been
considered the opposite of cardio protective. These foods have now been shown to decrease the
diversity of the microbiota. These findings suggest that the influence on the gut microbiota may
have been why these foods were shown to have a positive or negative influence on
cardiovascular health.
The gut microbiota has also been shown to change depending on a host’s health status.
Probiotic bacteria have been found to affect the make-up of the gut microbiota. Because of this it
is worth studying the cardiovascular benefits in manipulating the gut microbiota with probiotics
(Ahrén et al., 2014) . Probiotic bacteria in many studies have shown to have “significant
cholesterol-lowering properties” (Tomaro-Duchesneau et al., 2014, p.3). Probiotics may also
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have many advantages since they are found in many natural foods such as yogurt, cheaper than
most medications, and safe (Tomaro-Duchesneau et al., 2014).
According to Mistry (2014) there have been several strains of probiotics that have shown
to lower LDL cholesterol. These strains include L. reuteri, E. faccium, and L. acidophilus. The
effect that each one has on reducing cholesterol is variable. A meta-analysis by Zuang et al.
(2012) showed that probiotics in the diet can decrease total cholesterol by 6.4 mg/dl and LDL by
4.9 mg/dl. The mechanism is not fully understood. More research is needed because it is not well
known what probiotic strains and doses are needed to achieve maximum lipid lowering effects.
Probiotics have been shown to lower cholesterol through several mechanisms. One of the
mechanisms being cholesterol assimilation (Tomar-Duchesneau et al. (2014). A study by TomarDuchesneau et al. (2014) looked at different Lactobacillus strains and their ability to assimilate
cholesterol both in a culture media and simulated intestinal conditions. The results showed that
all the strains had the ability to assimilate cholesterol with Lactobacillus reuteri being the best
with the ability to assimilate 67% of the cholesterol. A study by Kumar et al. (2013) looked at
the effect of a probiotic Lactobacillus rhamnosus in combination with Aloe Vera on rats who had
high cholesterol. The study results show that serum cholesterol and LDL were decreased
significantly and HDL were increased significantly. Probiotics may be a warranted dietary
approach in decreasing cholesterol levels among many other health benefits.
Probiotics may also be able to decrease inflammation throughout the body which adds to
cardiovascular problems. L reuteri has been shown to decrease inflammatory markers in the
blood suggesting that probiotics may be able to decrease the risk of cardiovascular disease, type
2 Diabetes, and obesity. Probiotics, such as L. reuteri, should be considered an addition to a
healthy diet to help manage elevated LDL and may have a place in cholesterol treatment
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(DiRienzo, 2014) (Tomaro-Duchesneau et al., 2014). According to Direnzo (2014) “L. reuteri
capsules are the only probiotic capsules shown to significantly lower LDL” (p.20) and suggests
that more studies should be done regarding probiotics used in combination with statins.
Another risk factor for cardiovascular disease that probiotics may address is
hypertension. A systematic review by Khalesi et al. (2014) was done to look at probiotics and
what type of effect they have on blood pressure. Recent human studies have shown that oral
probiotic intake may have a positive effect on blood pressure control. Probiotics are throught to
improve blood pressure by decreasing total cholesteral, LDL, insulin resistance and acting on the
renin-angiotensin system. The systematic review looked at randomized control trials and
“overall, the results showed that consuming probiotics could significantly reduce systolic bolood
pressure by 3.56 mmHG and diastolic blood pressue by 2.38 mm HG.” (p.901). Most of the
studies used fermented milk but there were different types of probiotics used in some studies to
adequately give conclusions as to what probiotic is best in reducing blood pressure. Fermented
milk may have properties that act as angiotensin-converting enzyme inhibitors (Khalesi et al.,
2014).
A study by Ahrén et al. (2014) examined the anti-hypertensive effect of two combined
probiotics, blueberries and Lactobacillus plantarum, and the association with change in the gut
microbiota. The study was done in rats and after four weeks the results showed a significant drop
in blood pressure for the rats that received the probiotic compared to the rats that did not. There
was also a change in the gut microbiota for the rats that received the probiotic combination. The
results conclude that the probiotic product had significant anti-hypertensive effects which may
also decrease the risk of cardiovascular disease.
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Probiotics may act in different ways to control blood pressure. They may reduce
cholesterol with one meta-analysis showing a 6.4 mg/dL decrease in total cholesterol, a 4.9
mg/dL decres in LDL, and a 3.9 mg/dL decrease in triglycerides. They may regulate the RAS by
producing properties that act as angiontensin-converting enzyme inhibitors. Reducing weight
also decreases blood pressure but only one study showed an association in weight loss with
probiotics. Therefore probiotics may have a few different uses in decreasing the risk of
cardiovascular disease. The ability probiotics have shown to improve blood pressure control and
lipids potentiate the future use of probiotics in the treatment and prevention of high blood
pressure and high cholesterol. Future studies are needed to examine what strains of probiotics
and what amount is needed to gain maximum benefit (Khalesi et al., 2014).
Antibiotics increase blood pressure by altering the gut microbiota. Chronic systemic
inflammation can be due to a decrease in gut microbiota and the inflammation can be due to or a
result of hypertension (Jose & Raj, 2015). “Preeclampsia is associated with hypertension and
inflammation, the incidence of which is decreased by chronic intake of probiotics” (p.404).
Lactobacilli produce peptides that can inhibit angiotensin production and fermented milk when
ingested has been shown to lower blood pressure in humans who have hypertension. Blueberries
are also thought to decrease blood pressure by increasing the Lactobacilli in the gut (Jose & Raj,
2015).
Lastly, probiotics’ effect on the gut microbiota may positively impact weight regulation.
Obesity, diabetes, high cholesterol and hypertension are the main medical conditions that
influence cardiovascular risk (Ebel et al. 2014). “According to the WHO, these diseases are the
leading cause of worldwide morbidity and mortality” (p.177). New research suggests that the
bacteria in the gut may play a part in weight regulation since bacteria that is normally found in
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microbiota positively impacts “nutrient uptake and energy regulation” (p.178). A recent study on
obese mice showed that L. rhamnosus given over eight weeks reduced weight without change in
food intake. “The importance of the microbiota composition in obesity has been shown in model
laboratory organisms and confirmed in humans” p. (179). The effect of probiotics on decreasing
hypertension has not been studied as extensively as their effect on cholesterol but there are
several avenues that warrant investigation further. For example, there have been some bacteria
found to make nitric oxide which could be used for the vasodilatory effect in decreasing
hypertension.
In western civilization heart disease seems to go along with the chronic conditions
obesity, Type 2 diabetes, and inflammation. Those who are obese have a distinct gut microbiota
make up different from those who are lean. Overnutrition as well as a diet high in saturated fat,
cholesteral, and simple sugars changes the gut microbiota make up. Obesity is one of the main
risk factors for cardiovascular disease due to it being linked to type 2 diabetes, chronic
inflammation, and hyperlipidemia. A study was done on mice that showed a decrease in weight
after three weeks of Lactobacillus rhammosus or Lactobacillus sakei daily. There was no change
in what the mice ate or the amount. The results show that the change in gut microbiota lead to a
decrease in fat mass. A single probiotic may not get rid of obesity but understanding how the
microbiota effects “adipose tissue, cholesterol, satiety and other factors associated with
cardiovascular health, will contribute to identying new probiotic interventions” (Ettinger et al,
2014, p.722). Probiotics can be used to reestablish a healthy gut microbiotia of that of a lean
person to hopefully lose weight and prevent the cardiovascular detrimental effects (Ettinger et al,
2014).
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In conclusion, probiotics are very affordable compared to other medications such as ace
inhibitors, beta blockers, and statins without the side effects. Probiotics could decrease the cost
of these medications when used in combination. There is still a lot of investigating and
experimental studies that need to be done on the gut microbiota and the use of the probiotics to
treat and prevent cardiovascular disease but the potential is there for probiotics to become part of
therapy in cardiovascular disease (Ettinger et al., 2014). Modifying risk factors for
cardiovascular disease is the key to promote cardiovascular health and prevent cardiovascular
disease. Probiotics may have a place in the modification of risk factors for cardiovascular disease
such as high cholesterol, hypertension, and obesity. Further studies are warrented to determine
the strains and amount of probiotics necessary to get cardiovascular benefits.
Learning Points
•

Gut microbiota may be the new target for the prevention, treatment, and management of
cardiovascular disease

•

Probiotics may be able to lower cholesterol particularly low density lipid protein (LDL),
decrease hypertension, and help with maintaining a healthy weight by increasing gut
microbiota diversity

•

Probiotics are inexpensive, have less side effects compared to blood pressure and
cholesterol medications, and can easily be added to a healthy diet for example a probiotic
yogurt

•

Lactobacilli are the primary species shown to decrease cholesterol with L. reuteri
showing the most significant cholesterol lowering capability

•

The risk of cardiovascular disease can be significantly decreased through modifiable risk
factors and these risk factors should be addressed at each clinical visit
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